Otsuka strikes licensing deal of diabetes therapy

Otsuka Pharmaceutical has licensed the Japanese rights to Bristol-Myers Squibb's saxagliptin, being studied for the treatment of Type 2 diabetes. BMS gets an upfront payment and a schedule of milestones. Saxagliptin, discovered by Bristol-Myers Squibb, is a dipeptidyl peptidase-4 (DPP-4) inhibitor currently in Phase III development in the United States and Europe.

- here's the report on the deal from MedicalNewsToday